A Phase 2, Double-Blind, Placebo Controlled Study to Evaluate the Safety & Tolerability of PBI-4050 and Its Effects on Pancreatic and Pulmonary Function in Cystic Fibrosis Patients With Abnormal Glucose Tolerance

Trial Profile

A Phase 2, Double-Blind, Placebo Controlled Study to Evaluate the Safety & Tolerability of PBI-4050 and Its Effects on Pancreatic and Pulmonary Function in Cystic Fibrosis Patients With Abnormal Glucose Tolerance

Discontinued
Phase of Trial: Phase II

Latest Information Update: 09 Mar 2018

At a glance

  • Drugs PBI 4050 (Primary)
  • Indications Cystic fibrosis; Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Sponsors ProMetic Life Sciences
  • Most Recent Events

    • 28 Feb 2018 Status changed from recruiting to discontinued.
    • 21 Feb 2017 Status changed from not yet recruiting to recruiting.
    • 18 May 2016 According to ProMetic Life Sciences media release, company has received approval by Health Canada to commence this study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top